Apatinib, combined with chemotherapy or alone is effective in treating angiosarcoma: a case report. Issue 7 (August 2019)

• Record Type: Journal Article
• Authors: Liu, Mingyang; Liu, Yongmin; Guo, Huannan; Fu, Dongwei; Lv, Lili; Chen, Chunhong; Li, Yanlin; Zhang, Wenqian; Yao, Ming; Zhao, Limin
• Is Part Of: Anti-cancer drugs. Volume 30:Issue 7(2019)
• Publication Date: 2019-08
• Subjects: angiosarcoma -- apatinib -- vascular endothelial growth factor receptor; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000738
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Angiosarcomas are rare but aggressive tumors with poor prognosis. The treatment of angiosarcomas with vascular endothelial growth factor receptor inhibitors is still in the stage of clinical exploration. Herein we reported a patient of skin angiosarcoma with multiple organ metastasis. She was resistance to multiline chemotherapy and pazopanib but achieved remarkable shrinkage of the lesion after apatinib treatment combined with chemotherapy or alone. The progression-free survival of the primary lesion with KRAS V14I and RBM10 E119D mutations (10 months) was shorter than that of the brain without the mutation ( ≥ 12 months). Although it is not clear whether the KRAS V14I and RBM10 E119D mutations are the main factors that impact the effect of apatinib treatment or not, the results of this study will provide valuable clues for relevant follow-up basic and clinical studies.